Back to discover
Disease

Lower respiratory tract disorder

Also known as disease of lower respiratory tract, disease or disorder of lower respiratory tract, disorder of lower respiratory tract, lower respiratory tract disease+1 more

disease of lower respiratory tract, disease or disorder of lower respiratory tract, disorder of lower respiratory tract, lower respiratory tract disease, lower respiratory tract disease or disorder.

12
Associated genes
4
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 regulatory approval from EMA on record.
Major developments
Important regulatory approvalHigh impact
Approval — Clesrovimab
Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.2026-04-15
Regulatory Updates1View
  • 2026-04-15Approval — ClesrovimabEnflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.
Activity timeline1
  • 2026-04-15RegulatoryApproval — ClesrovimabEnflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Clesrovimabapproved

Approval — Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower resp… (2026)

Nirsevimabapproved

Approval — Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower resp… (2022)

Palivizumabapproved

Approval — Synagis is indicated for the prevention of serious lower-respiratory-tract disease requir… (1999)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2026emaApproval — Clesrovimab· Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations. source ↗
2022emaApproval — Nirsevimab· Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:i.        Neonates and infants during their first RSV season.ii.        Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see section 5.1).Beyfortus should be used in accordance with official recommendations. Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:i.          Neonates and infants during their first RSV season.ii.         Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see section 5.1).Beyfortus should be used in accordance with official recommendations. source ↗
1999emaApproval — Palivizumab· Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease: children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season; children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months; children less than two years of age and with haemodynamically significant congenital heart disease. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

IL4R0.47NPNT0.44THSD40.37TBX210.36OTULINL0.34NDFIP10.31SEC61B0.30TNFRSF6B0.30TSPAN80.29ARRDC10.29SUMF10.28EFHC10.28

Disease biology

4 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Interleukin-4 receptor subunit alphavia IL4R0.47T-box transcription factor TBX21via TBX210.36Chitinase-3-like protein 1via CHI3L10.14Granulocyte colony-stimulating factorvia CSF30.13

Reference

Authoritative identity, definition & identifiers.

Synonyms

disease of lower respiratory tract, disease or disorder of lower respiratory tract, disorder of lower respiratory tract, lower respiratory tract disease, lower respiratory tract disease or disorder

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.